Iron Chelation Enhances TAM and Triple-Negative Breast Cancer Cell Death
Technical Report,15 Sep 2018,14 Sep 2019
Sloan Kettering Institute for Cancer Research New York United States
Pagination or Media Count:
The goal of this study is to complete preclinical testing of Deferiprone DFP, an iron chelator in clinical use for non-oncologic diseases. To date we have demonstrated that DFP has an IC50 for TNBC within the range achieved after a clinical dose, and enhances the effect of taxol in 4T1 tumors. The IC50 for tumor cells was lower than measured for macrophages M0, M1, M2 indicating potential therapeutic gain and safety in treating cancer cells. In 4T1 tumors, DFP did not change iron concentration measured in tissues spleen and tumor. In perfused 4T1 cells, we demonstrated metabolic inhibition of the tricarboxylic acid cycle and lipid metabolism by DFP and similar studies are ongoing in the MDA-231. We have measured lactate in tumors control and DFP treated and the data are currently undergoing analysis.
- Medicine and Medical Research
- Organic Chemistry